Fundz

Arri Vent Biopharma, Inc. reported raising $81 Million in an initial SEC Form D filing, from an offering of $90 Million

PUBLIC · ABUSJun 23, 2021$81M of $90M raised

Amount Raised

$81 Million

$81 Million sold, per SEC Form D (first sale Jun 23, 2021)

Round Type

Venture

WarminsterBiotechnologyHealthcareHealth CareTherapeuticsPharmaceuticalBiopharma

Quick answer

Arbutus raised $81 Million in a funding round, dated June 23, 2021. Arbutus is based in Warminster, Pennsylvania, United States.

How much did Arbutus raise?
Arbutus raised $81 Million in a funding round on June 23, 2021.
What does Arbutus do?
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which..
Where is Arbutus based and how big is it?
Arbutus is based in Warminster, Pennsylvania, United States.
Who are the decision-makers at Arbutus?
Fundz holds 1 contact at Arbutus. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Healthcare and Therapeutics around the same time

Companies in the same sectors as Arbutus that raised within 45 days of this round, from Fundz verified event records.

  • Amylyx Pharmaceuticals raised $135M (Series C) on July 20, 2021.
  • Azora Therapeutics, Inc. (DE) raised $500K on July 12, 2021.
  • Zevra Therapeutics, Inc. raised $39M on June 22, 2021.
  • Ajax Therapeutics, Inc. raised $37M on June 1, 2021.
  • Nuvalent raised $135M on May 12, 2021.
  • Nuvalent raised $135M (Series B) on May 11, 2021.

Who to call at Arbutus, and when

A new round usually means Arbutus is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Arbutus raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Arbutus, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Arbutus. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Arbutus

Location

701 Veterans Circle

Warminster, Pennsylvania, United States

About

Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. Additionally, we have identified compounds in our internal PD-L1 portfolio that could also be used in oncology indications. For more information, visit www.arbutusbio.com.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Arbutus raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts15 people are listed at Arbutus. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Arbutus's next move

See what Strategic adds

Arbutus raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.